Daniel Ebner
Research groups
Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models
Elliott RJR. et al, (2024)
-
The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity
Hmedat ANA. et al, (2024)
-
A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Bleloch JS. et al, (2024), Cancer medicine, 13
-
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Kent D. et al, (2024), Hepatology (Baltimore, Md.)
-
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Pouwels KB. et al, (2024), Nature communications, 15